ArticleFrontiers in microbiology2022
Cell Membrane Remodeling Mediates Polymyxin B Resistance in
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Metabolism-Based Biomarkers for Rapid Phenotypic Antibiotic Susceptibility Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Proteome-wide remodelling in Klebsiella pneumoniae during step-wise adaptive evolution against colistin.PloS one · 2026Article
- Integrated Proteomics and Metabolomics Reveal Multifaceted Mechanisms of Colistin Resistance inInfection and drug resistance · 2026Article
- Hyperforin potentiates polymyxin B against multidrug-resistant Gram-negative pathogens via membrane disruption, biofilm eradication, and oxidative stress.Antimicrobial agents and chemotherapy · 2025Article
- Phenyllactic Acid as a Marker of Antibiotic-Induced Metabolic Activity of Nosocomial Strains ofMicroorganisms · 2025Article
- Insights into the Metabolic Adaptations of a Carbapenem-ResistantInternational journal of molecular sciences · 2025Article
- Prevalence of polymyxin heteroresistance in Klebsiella pneumoniae under sustained antibiotic selection during experimental evolution.Archives of microbiology · 2025Article
- Genomic diversity and functional insights of carbapenem-resistantMicrobial genomics · 2025Article
- Antibiotic potentiators as a promising strategy for combating antibiotic resistance.npj antimicrobials and resistance · 2025Review
- CD38 Coordinates with NF-κB to Promote Cochlear Inflammation in Noise-Induced Hearing Loss: the Protective Effect of Apigenin.Molecular neurobiology · 2025Article
- Antibiotic resistance and epidemiological characteristics of polymyxin-resistantZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Roles of qseC mutation in bacterial resistance against anti-lipopolysaccharide factor isoform 3 (ALFPm3).PloS one · 2023Article
- In vitro Activity of Cefepime/Avibactam Against Carbapenem ResistantInfection and drug resistance · 2023Article
- Molecular Characteristics and Quantitative Proteomic Analysis ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxin B (PB) is introduced into the clinic as the last-line therapy against carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.